Orthofix International N.V. announced preliminary unaudited sales results for the fourth quarter and full year ended December 31, 2017. For the quarter, the company reported total net sales of USD 116.9 million compared to USD 108.5 million a year ago.

For the year, the company reported total net sales of USD 433.8 million compared to USD 409.8 million a year ago.

For the full year 2018, the company expects to report net sales of USD 450 million to USD 455 million based on current foreign exchange rates, which reflects reported growth of approximately 4% to 5%. This guidance includes a positive currency impact of approximately USD 4.0 million, offset by an estimated USD 4.0 million decrease in the 2018 marketing services fee the company receives from MTF Biologics. This decrease is due to the final contractual step-down in the fee that Orthofix receives from MTF Biologics for sales of Trinity ELITE and Trinity Evolution from 65% to 60%. The company expects 100 basis points adjusted EBITDA margin improvement in each of the next 3 years.